Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its H-share Full Circulation plan.

The conversion involves six participating shareholders, collectively holding 68.97% of the company’s issued share capital as of 17 April 2026. Key participants include Xuanzhu (HK) Biopharmaceutical (215.29 million shares, 41.57% post-conversion) and Sihuan Pharmaceutical Holdings Group (39.16 million shares, 7.56%). Upon completion, Xuanzhu’s entire issued share capital—517.95 million shares—will be tradable as H shares on the HKEX, eliminating the previous 68.97% block of unlisted shares.

The company will complete the required conversion and trading procedures and will update the market on further progress. Investors are advised to exercise caution when dealing in Xuanzhu Biopharmaceutical shares.